Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Research on locomotion of giraffes valuable for conservation of this species
2016-08-23

Description: Giraffe research 2016 Tags: Giraffe research 2016

Technology was used in filming the giraffes.
According to research, giraffes will slow
down when a drone is positioned
approximately 20 - 30 m away. When the
drone moves closer, they will revert
to galloping.
Photo: Charl Devenish


The meaning of the Arab term Giraffe Camelopardalis is ‘someone who walks fast’. It is precisely this locomotion of their longnecks that encouraged researchers, Dr Francois Deacon and Dr Chris Basu, to study the animals more closely.

Despite the fact that giraffes are such well-known animals, very little research has been done on the manner in which these graceful animals locomote from one place to the next. There are only two known ways of locomotion: the slower lateral walking and the faster galloping. Most animals use these ways of moving forward. It is unknown why giraffes avoid intermediate-speed trotting.

Research of great value to the industry

Research on the manner in which giraffes locomote from one place to the next will assist the industry in understanding aspects such as their anatomy and function, as well as the energy they utilise in locomoting from one place to another. Information on the latter could help researchers understand where giraffes fit into the ecosystem. This data is of great value for large-scale conservation efforts.

Universities working together to collect data

Dr Basu, a veterinarian at the Royal Veterinary College in the UK, has studied the animals at a zoo park in the United Kingdom. He visited the University of the Free State (UFS) in order to expand his fieldwork on the locomotion of giraffes. This study was done in cooperation with Dr Deacon from the Department of Animal, Wildlife, and Grassland Sciences at the UFS. Dr Deacon is a specialist in giraffe habitat-related research in South Africa and other African countries.

The fieldwork for the research, which was done in the Woodland Hills Wildlife Estate and the Willem Pretorius Nature Reserve, preceded research on the movement and the forces involved in the locomotion of giraffes. Due to the confined fenced area in the zoo park, it was practically impossible to study the animals at speed. “The study of actions ‘faster than walking’ is crucial for gathering data on, inter alia, the frequency, length, and time associated with each step.


Technology such as drones offers unique
opportunities to study animals like giraffes.



Technology used to ensure accuracyTechnology such as drones offers unique opportunities to study animals like giraffes. Apart from the fact that it is possible to get high-quality video material of giraffes – moving at speed – it is also a very controlled device that ensures the accuracy of data.

It is the first time ever that a study has been done on the locomotion of giraffes with this level of detail.
Research on the study will be published in the Journal of Experimental Biology.

The project was approved by the UFS ethics committee.

 

 

 

Previous research articles:

9 March 2016:Giraffe research broadcast on National Geographic channel
18 Sept 2015 Researchers reach out across continents in giraffe research
29 May 2015: Researchers international leaders in satellite tracking in the wildlife environment


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept